These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29503545)

  • 1. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine.
    Imagawa H; Nagar SP; Montgomery W; Nakamura T; Sato M; Davis KL
    Neuropsychiatr Dis Treat; 2018; 14():611-621. PubMed ID: 29503545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world analysis of treatment change and response in adults with attention-deficit/hyperactivity disorder (ADHD) alone and with concomitant psychiatric comorbidities: results from an electronic health record database study is the United States.
    Liman C; Schein J; Wu A; Huang X; Thadani S; Childress A; Kollins SH; Bhattacharjee S
    BMC Psychiatry; 2024 Sep; 24(1):618. PubMed ID: 39285361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
    Benkert D; Krause KH; Wasem J; Aidelsburger P
    GMS Health Technol Assess; 2010 Sep; 6():Doc13. PubMed ID: 21289886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Kabul S; Alatorre C; Montejano LB; Farr AM; Clemow DB
    CNS Neurosci Ther; 2015 Dec; 21(12):936-42. PubMed ID: 26331467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors that Affect the Adherence to ADHD Medications during a Treatment Continuation Period in Children and Adolescents: A Nationwide Retrospective Cohort Study Using Korean Health Insurance Data from 2007 to 2011.
    Bhang SY; Kwack YS; Joung YS; Lee SI; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ; Hwang JW
    Psychiatry Investig; 2017 Mar; 14(2):158-165. PubMed ID: 28326113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
    Song I; Shin JY
    Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    PLoS One; 2020; 15(5):e0232738. PubMed ID: 32442204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.
    Clemow DB; Bushe C; Mancini M; Ossipov MH; Upadhyaya H
    Neuropsychiatr Dis Treat; 2017; 13():357-371. PubMed ID: 28223809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
    Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
    Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.